United Therapeutics Reports Record Q2 2025 Financial Results

United Therapeutics Corp. ( (UTHR) ) has released its Q2 earnings. Here is a breakdown of the information United Therapeutics Corp. presented to its investors.

United Therapeutics Corporation, a public benefit biotech company, specializes in developing pharmaceutical therapies and technologies to expand transplantable organ availability, with a focus on treating pulmonary diseases.

United Therapeutics Corporation reported record financial results for the second quarter of 2025, with total revenues reaching $799 million, marking a 12% increase compared to the same period in 2024. The company also announced a share repurchase program of up to $1 billion, reflecting confidence in its financial position and future growth prospects.

Key financial highlights include a significant revenue boost from Tyvaso DPI, which saw a 22% increase, contributing to total Tyvaso revenues of $469.6 million, an 18% rise year-over-year. Other products like Nebulized Tyvaso, Orenitram, and Unituxin also experienced double-digit growth. The company completed enrollment for its phase 3 ADVANCE OUTCOMES study of ralinepag and anticipates data from the TETON 2 study in September 2025.

The company’s net income for the quarter was $309.5 million, up 11% from the previous year, with earnings per share also showing a notable increase. Operating expenses rose due to increased research and development activities and higher general and administrative costs, but the overall financial health remains robust with substantial cash reserves.

Looking ahead, United Therapeutics remains optimistic about sustained revenue growth driven by its strong commercial execution and promising late-stage pipeline. The company is poised to continue its innovative efforts in addressing unmet medical needs in pulmonary diseases and organ transplantation technologies.